Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
Division of Radiation Oncology, Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA.
J Appl Clin Med Phys. 2019 Jun;20(6):31-38. doi: 10.1002/acm2.12592. Epub 2019 Apr 19.
Transrectal ultrasound images are routinely acquired for low dose rate (LDR) prostate brachytherapy dosimetric preplanning (pTRUS), although diagnostic multiparametric magnetic resonance imaging (mpMRI) may serve this purpose as well. We compared the predictive abilities of TRUS vs MRI relative to intraoperative TRUS (iTRUS) to assess the role of mpMRI in brachytherapy preplanning.
Retrospective analysis was performed on 32 patients who underwent iTRUS-guided prostate LDR brachytherapy as either mono- or combination therapy. 56.3% had pTRUS-only volume studies and 43.7% had both 3T-mpMRI and pTRUS preplanning. MRI was used for preplanning and its image fusion with iTRUS was also used for intraoperative guidance of seed placement. Differences in gland volume, seed number, and activity and procedure time were examined, as well as the identification of lesions suspicious for tumor foci. Pearson correlation coefficient and Fisher's Z test were used to estimate associations between continuous measures.
There was good correlation of planning volumes between iTRUS and either pTRUS or MRI (r = 0.89, r = 0.77), not impacted by the addition of hormonal therapy (P = 0.65, P = 0.33). Both consistently predicted intraoperative seed number (r = 0.87, r = 0.86). MRI/TRUS fusion did not significantly increase surgical or anesthesia time (P = 0.10, P = 0.46). mpMRI revealed suspicious focal lesions in 11 of 14 cases not visible on pTRUS, that when correlated with histopathology, were incorporated into the plan.
Relative to pTRUS, MRI yielded reliable preplanning measures, supporting the role of MRI-only LDR treatment planning. mpMRI carries numerous diagnostic, staging and preplanning advantages that facilitate better patient selection and delivery of novel dose escalation and targeted therapy, with no additional surgical or anesthesia time. Prospective studies assessing its impact on treatment planning and delivery can serve to establish mpMRI as the standard of care in LDR prostate brachytherapy planning.
经直肠超声(TRUS)图像通常用于低剂量率(LDR)前列腺近距离放射治疗剂量学的预规划(pTRUS),尽管诊断性多参数磁共振成像(mpMRI)也可以达到这一目的。我们比较了 TRUS 与 MRI 相对于术中 TRUS(iTRUS)的预测能力,以评估 mpMRI 在近距离放射治疗预规划中的作用。
对 32 例接受 iTRUS 引导的 LDR 前列腺近距离放射治疗的患者进行回顾性分析,这些患者采用单一治疗或联合治疗。56.3%的患者仅进行了 pTRUS 体积研究,43.7%的患者同时进行了 3T-mpMRI 和 pTRUS 预规划。MRI 用于预规划,其与 iTRUS 的图像融合也用于术中引导种子放置。检查了腺体体积、种子数量和活性以及手术时间的差异,并识别了疑似肿瘤病灶的病变。使用 Pearson 相关系数和 Fisher's Z 检验估计连续测量之间的关联。
iTRUS 与 pTRUS 或 MRI 之间的计划体积具有良好的相关性(r=0.89,r=0.77),不受激素治疗的影响(P=0.65,P=0.33)。两者均能很好地预测术中种子数量(r=0.87,r=0.86)。MRI/TRUS 融合并没有显著增加手术或麻醉时间(P=0.10,P=0.46)。mpMRI 在 14 例中发现了 11 例 pTRUS 上不可见的可疑局灶性病变,这些病变与组织病理学相关联,并被纳入计划中。
与 pTRUS 相比,MRI 提供了可靠的预规划指标,支持仅使用 MRI 进行 LDR 治疗计划。mpMRI 具有许多诊断、分期和预规划优势,有助于更好地选择患者,并提供新的剂量升级和靶向治疗,而不会增加手术或麻醉时间。评估其对治疗计划和实施影响的前瞻性研究可以确立 mpMRI 作为 LDR 前列腺近距离放射治疗计划的标准。